Lycia Therapeutics’ Post

Today marks the first day of trading in Trill Impact’s portfolio company Cinclus Pharma on Nasdaq Stockholm. The listing is an important milestone that enables continued development of the company’s drug candidate linaprazan glurate, which aims to improve the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide.   Nina Rawal, Partner at Trill Impact Advisory and Co-head of Trill Impact Ventures was present when the opening bell rang this morning.   “It is of course very exciting to see Cinclus Pharma being listed on Nasdaq Stockholm today. To us, the fact that Cinclus Pharma has attracted investor interest in the current financial climate, is a great testament to the quality of the asset and the strong management team. When Trill Impact invested in Cinclus Pharma a couple of years back, we were confident that the company had the potential to become a global leader in the treatment of severe gastric acid-related disease. Since then, the company has reported strong Phase II data and is now ready to move into the final stage of clinical development". Read more about the #IPO here: https://lnkd.in/d7tvcBPC #impactinvesting #biotech #healthcare #lifescience #SDG3

Cranmore Executive Search played a pivotal role in Horizon's rapid and successful expansion into the European market. "I highly recommend Cranmore," says Chris Serafino. "My contact, Chris Sannwald is a very effective partner and helps me not only find the right candidate and fit, but also is patient with me as my needs grow or change." Read the full case study below on how Cranmore's tailored approach to executive search empowered Horizon Therapeutics' European expansion and fuelled their remarkable success! 📈✨ #SuccessStories #ExecutiveSearch #EuropeanExpansion #HorizonTherapeutics

Today BenevolentAI announces an update on our business priorities: 👉 We will focus on our drug discovery collaboration and proprietary pipeline revenue-generating pillars, following recent successes in both these areas, such as the recent Phase 1a data readout for our lead asset BEN-8744 for the treatment of ulcerative colitis 👉 Work on the Knowledge Exploration Tools will end, with proposed headcount reductions, meaning we can increase cash runway to late Q3 2025 👉 Importantly, key skills, experience and capabilities have been retained and these reductions do not diminish the Company’s ability to execute on existing, or sign new, collaborations and continue to develop its core pipeline programmes 💬 Our CEO Joerg Moeller: “I believe that focusing our organisation on furthering our drug discovery collaborations and progressing our proprietary pipeline is the best way of delivering value creation for our shareholders and delivering innovative medicines to patients suffering from very serious medical conditions”. You can read more here https://lnkd.in/eJ9pDHfN

Recording of the webinar "The Digital Therapeutics Ecosystem: And Why It Matters" is available now! For those unable to attend or want to review the discussion, please follow the link below: https://lnkd.in/e76A_3_u Thanks to our speakers Andy Molnar, Poorva Dharkar, Ph.D. MBA, Abigail Holland, Alex G. Lee, Ph.D. Esq., Dr Arrash Yassaee, and Jose Garcia for sharing their in-depth insights and knowledge. Stay tuned for more updates and materials coming soon!🚀 #DigitalTherapeutics #WebinarRecording #TechInnovations #HealthTech #DigitalHealth #DigitalTherapeuticsEcosystem

Centogene runs amazing science and technology, but its commercial model - like so many other genomics companies - lacks. The industry urgently needs a new layer of companies that are systems integrators for hospitals and turn these amazing genomics technologies - including software, AI and decision support systems as well as combination therapies, which are all downstream of genomics - in oncology and beyond btw - into REAL commercial and medical value chains for hospitals. That's the only way to align groundbreaking science + tech to medical and financial value. We are on it!

Despite recent IPO fluctuations, American Healthcare REIT, Fortegra Group, and Fractyle Health forge ahead, indicating resilience in the market. American Healthcare REIT leads with an impressive $869 million, showcasing ongoing investor confidence. Fortegra Group and Fractyle Health, though smaller in scale, contribute to the diverse offerings. The varied IPO performances of CG Oncology and BrightSpring Health underline the market's unpredictability. Amer Sports adds to the mix, emphasizing sustained IPO activity. While challenges persist, these healthcare, insurance, and biotech ventures demonstrate a collective commitment to navigating the dynamic IPO landscape, seizing opportunities, and adapting to market dynamics. #biotech #ipo #healthcareinvesting

🚨 Centogene Delisted from Nasdaq: A Reflection on a Once Proud Flagship 🚨 It’s with a heavy heart that I observe CENTOGENE‘s delisting from Nasdaq, a stark reminder of the challenging times the diagnostics industry is facing. 📉 Just a few years ago, Centogene stood as a beacon of innovation in rare disease testing, boasting a market value exceeding $200 million. Today, that valuation has plummeted to less than $10 million. 📉This downturn is not just the result of unfavorable market conditions but also a broader reckoning within our industry. Many diagnostics companies are struggling with profitability, and leadership transitions have further complicated the path forward. 🧬Centogene’s story is particularly poignant given its deep heritage and vital mission to serve rare disease patients globally. 🔮While now may not be the time to speculate on the company’s future, I sincerely hope that the remarkable work the Centogene team has done for the rare disease community is preserved in some form. The legacy of their contributions should not be forgotten, no matter what the future holds. 🔗 https://lnkd.in/dDyXWh4A #Diagnostics #Healthcare #Leadership #RareDiseases #Centogene #Biotech

Two years after taking up the mantle as Managing Director at X-ZELL, I am proud to announce that our Next-Generation Cytology technology is now listed with the US Food and Drug Authority (FDA) and compliant with Europe’s CE-IVDR regulation. I can’t even begin to describe how exciting it is to have achieved this milestone. I may all sound a bit technical, but let me assure you it's a huge win and the result of years of hard work. It will not only pave the way for direct market access in Europe and the US, but also ensure we are compliant with the biggest regulatory change in recent history – the switch from IVDD to IVDR in Europe, which began in 2022 and will conclude in May 2027. Put differently, it’s our ticket to play in a whole different league. Safe to say the past two years have been a wild ride for everyone at X-ZELL, both in Asia and Europe. Thank you to everyone involved – including our amazing staff, investors, families, friends and everyone who cheered us on from the sidelines – for helping us get here. A special shout-out to our Head of Engineering & Product Development, Sven Strache, and our Head of Clinical, Quality & Regulatory Affairs, Claire Fives, for your tireless work on this project – you rock! Full story here: https://lnkd.in/eiPaXrJM #startup #growth #milestone #medtech #cancerdiagnostics #cytology #pathology #nextgenerationcytology #digitalhealth

2024 has marked a new phase for biopharma partnerships and doing the “exact” deal is more important than ever to advance innovation and accelerate groundbreaking new therapies to patients. I look forward to joining a panel discussion at #LSXUSA, September 11 in Boston, MA. I’ll be discussing how strategic fit and creative deal-making are shaping the partnerships that will deliver positive, sustainable and meaningful value to patients. Come join us if you’re attending: https://bit.ly/46JeXh3 #ScienceFirstForPatients #ChangingTomorrow

Earlier this year, Headlands Research CEO, Kyle Burtnett, joined other experts as a panelist for a discussion on Clinical Trial Site Management Organizations (SMOs) during a session at the inaugural Pharma and MedTech Services Investment Summit. The panelists discussed the role that SMOs and dedicated clinical trial sites play within the life sciences industry, what makes them attractive to investors, and the key criteria investors evaluate when considering opportunities to back or acquire a trial site. Check out some of the key takeaways from the session >> bit.ly/3yhtpjn #myAMCR #HeadlandsResearchAMCR #ClinicalTrials #ClinicalResearch #ClinicalResearchTrials #ClinicalResearchSite